off-label use

Zytiga to be Considered for Use in Men with Advanced Prostate Cancer Prior to Chemotherapy

Yesterday, Johnson & Johnson announced that it has asked U.S. and European Union regulators to grant broader marketing approval for its cancer pill, Zytiga which is used to treat men with castrate resistant prostate cancer. Zytiga was approved in 2011 for the treatment of advanced prostate cancer in men who have received chemotherapy and who [...]

By Malecare|2012-06-16T20:57:22-04:00June 16th, 2012|abiraterone acetate, Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, FDA, Uncategorized|0 Comments

Prominent Attorney with Terminal Cancer Gets Tysabri After Biogen Idec’s Earlier Denial- Its Implications for Prostate Cancer Treatment

A prominent attorney, Frederick Baron, who is dying of bone marrow cancer, has been granted his wish, to receive the drug Tysabri. After significant wrangling, The FDA and the Mayo Clinic found a legal basis to give him the drug in an emergency situation, even though Tysabri is not approved for any cancers. This decision [...]

By Malecare|2017-10-19T10:56:55-04:00October 22nd, 2008|Advanced Prostate Cancer, Advocacy, Clinical Trials, Drugs & Treatments, Uncategorized|0 Comments